Law Firms Urge Telix Investors to Seek Lead Plaintiff Status Before Jan. 9 Deadline

The case alleges Telix overstated prostate therapy progress plus supplier quality, with losses tied to SEC and FDA disclosures.

Overview

Multiple investor firms, including The Rosen Law Firm, The Gross Law Firm, and Glancy Prongay & Murray, are reminding shareholders of the January 9, 2026 deadline to move for lead-plaintiff appointment.
The putative class covers purchasers of Telix securities between February 21, 2025 and August 28, 2025.
Plaintiffs claim Telix misled investors by overstating progress on prostate cancer therapeutic candidates and the reliability of third‑party manufacturing partners.
Noted disclosures include a July 22, 2025 SEC subpoena regarding prostate therapeutics statements and an August 28, 2025 FDA Complete Response Letter citing CMC deficiencies, each followed by double‑digit share declines.
No class has been certified and the litigation is at an early stage in federal court, with lead-plaintiff motions pending.